Anavex Life Sciences to Participate in the Cantor Virtual Rare Orphan Disease Summit
March 28, 2022 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, March 28, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Anavex Life Sciences Announces Presentation of Phase 2 Clinical Biomarker Data from ANAVEX®2-73-PDD-001 Parkinson’s Disease Dementia Study at AD/PD™ 2022 International Conference
March 15, 2022 07:00 ET
|
Anavex Life Sciences Corp.
All MDS-UPDRS Part I, II, III, IV sub-scores improved, including substantial majority of individual items between 71% and 92% SIGMAR1 mRNA expression significantly increased in ANAVEX®2-73-treated...
Anavex Life Sciences to Participate in the Annual Needham Virtual Neuroscience Forum
March 09, 2022 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, March 09, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Anavex Life Sciences Announces Change of Auditor to Grant Thornton LLP
March 04, 2022 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, March 04, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Anavex Life Sciences to Present at the 11th Annual SVB Leerink Global Healthcare Conference
February 10, 2022 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Anavex Life Sciences Provides Business Update and Reports Fiscal 2022 First Quarter Financial Results
February 09, 2022 07:00 ET
|
Anavex Life Sciences Corp.
Company to host a webcast today at 4:30 p.m. Eastern Time NEW YORK, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...
Anavex Life Sciences Provides Supplemental Information on ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial for the Treatment of Adult Patients with Rett Syndrome
February 04, 2022 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
Anavex Life Sciences to Announce Fiscal 2022 First Quarter Financial Results on Wednesday, February 9, 2022
February 03, 2022 07:00 ET
|
Anavex Life Sciences Corp.
NEW YORK, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics...
ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial met Primary and Secondary Efficacy Endpoints for the Treatment of Adult Patients with Rett Syndrome
February 01, 2022 07:00 ET
|
Anavex Life Sciences Corp.
Primary and all secondary efficacy and safety endpoints met, with consistent improvements in RSBQ AUC (p = 0.037), ADAMS (p = 0.010) and CGI-I (p = 0.037) response Efficacy endpoints demonstrated...
Anavex Life Sciences Reports Positive Results from Phase 1 Clinical Trial of ANAVEX®3-71
January 10, 2022 07:00 ET
|
Anavex Life Sciences Corp.
Study reached primary and secondary endpoints of safety, respectively ANAVEX®3-71 well tolerated as oral administration in all dose cohorts No serious adverse events or dose-limiting toxicities...